Navigation Links
BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
Date:11/15/2007

BRUSSELS, Belgium and BRISBANE, Calif., Nov. 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced it has initiated a Phase 2 study of its lead PARP inhibitor, BSI-201, in patients with triple-negative breast cancer that do not express the estrogen, progesterone or HER2 receptors.

The company designed the Phase 2 trial in this indication-which represents a major unmet medical need-based on molecular biomarker data presented today showing that breast tumors that are estrogen-negative and progesterone- negative were more likely to overexpress PARP, as were HER2-negative tumors. The data were presented at European Organization for Research and Treatment of Cancer-National Cancer Institute-American Society for Clinical Oncology Annual Meeting on "Molecular Markers in Cancer" in Brussels.

"Our research shows clearly that not only is PARP overexpressed in breast tumors generally, it is even more likely to be overexpressed in triple- negative tumors. That suggests that PARP inhibition may be a particularly effective way to target those hard-to-treat cancers," said BiPar Executive Vice President Barry Sherman, M.D. "Our Phase 2 trial of BSI-201 will build on those insights and, if successful, will serve as powerful proof of our strategy to use molecular biomarker data to focus our clinical studies of BiPar's PARP inhibitors on tumors that markedly upregulate PARP."

Patients with triple-negative breast cancer, who make up 10 to 15 percent of all patients, have few effective therapeutic options. Neither targeted therapies such as Herceptin and Tykerb nor anti-estrogens such as tamoxifen provide a benefit, and triple-negative tumors are associated with a high rate of relapse. Such cancers are particularly prevalent in premenopausal African- American women.

"We are very excited about being able to offer patients with triple- negative metastatic breast cancer treatment
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
5. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
6. Enrollment Begins on Human PK Study for Medidur(TM) FA
7. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
8. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
9. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
10. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
11. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Apnea Sciences ( www.apneasciences.com ) ... Aliso Viejo , California.  Jimmy ... tremendous growth and worldwide expansion, a new facility with ... the anti snore cure have exceeded our expectations and ... are now in 23 countries and will be increasing ...
(Date:12/22/2014)... MEMPHIS, Tenn. , Dec. 22, 2014   ... only automated, no-touch UV disinfection robot, announced today that ... GSA Schedule contract through November 2019.   ... to rapidly engage all levels of government purchasers, including ... facilities, as well as Homeland Security contacts purchasing solutions ...
(Date:12/22/2014)...  ConvaTec, a privately-held medical products and technologies company, ... Chief Executive Officer of the company, effective December 22, ... .  "The Board of Directors of ConvaTec thanks Mr. ... past three years," said Magnus Lundberg , the ... that the company is well positioned for the future."  ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... SAN DIEGO, Oct. 27 Orexigen® Therapeutics, Inc. (Nasdaq: ... (ITT) analyses from the COR-I and COR-II Phase 3 trials ... stage Orexigen candidates for the treatment of obesity. These ... findings from a panel discussion on Saturday where the Company ...
... from a phase II study demonstrated that oral ... frequency of bowel movements in patients with opioid-induced ... an oral peripherally-acting opioid antagonist, is an investigational ... of opioid-induced constipation. , (Logo: ...
Cached Medicine Technology:Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 2Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 3Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 4Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 5Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 6Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego 2Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego 3Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego 4
(Date:12/24/2014)... 2014 Dr. Svetlana Gomer, MGS Tewksbury ... nation gathered with US Marines on November 14, 2014 ... for the Toys for Tots Literacy Program. This ... new books and audio books for the Toys for ... this Christmas. It represents another major strike in the ...
(Date:12/24/2014)... The report offers details on the global sports ... such as the key trends, the orthopedic market, the ... U.S. sports medicine, the impact of the global economy ... by the market. , Browse report with table of ... provides an overview of the global as well as ...
(Date:12/24/2014)... GA (PRWEB) December 24, 2014 Verde Pointe ... comical than ever. "Last years homemade Christmas sweater lit ... uglier. The 2014 winner is Tandy Wilson for the ... ugly sweater enthusiast," says Kirk Kimmerling DDS. "She took pictures ... angels on the sweater." , "Every year I ...
(Date:12/24/2014)... FL (PRWEB) December 24, 2014 Dental ... solution for a tooth replacement. They offer the strongest ... several advantages over other forms of tooth replacement. They ... rely on the adjacent teeth for support, and they ... people have been told that they are not suitable ...
(Date:12/24/2014)... Attorneys handling talcum powder cancer lawsuits at ... website, the Talcum Powder Ovarian Cancer Center. ... action lawsuits and ovarian cancer claims. These baby powder ... at their website, which serves as a national public ... are not the same as class action lawsuits,” explains ...
Breaking Medicine News(10 mins):Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2Health News:Verde Pointe Dental Associates Announces the 2014 Ugly Sweater Holiday Contest Winner 2Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 4
... (HealthDay News) -- Some HIV patients experience memory loss ... suggests that the reason why is because the virus ... of supporting brain cells called astrocytes. The blood-brain ... the brain from harmful chemicals and toxins. In healthy ...
... teaming up to offer one of the nation,s most ... Led by the University of Maryland and the ... will target the so-called short-haul "drayage" fleet that shuttles ... The effort seeks to double the impact of ...
... News) -- Cancer patients taking the drugs sunitinib and ... the drugs don,t cause as much damage to the ... small study included 40 volunteers in the Netherlands, including ... were treated with sorafenib. Seven patients with metastatic renal ...
... Kathleen Doheny HealthDay Reporter , TUESDAY, June 28 ... more than most experts have long believed, according to a ... follow-up of nearly three decades -- the longest ever -- ... clearer as the decades roll on. In fact, most ...
... 2011 Earl L. Smith III, O.D., dean of the ... received an award for his work in slowing the progression ... the endowed Greeman-Petty Professor chair, accepted the Donald Korb Award ... lens and cornea section of the American Optometric Association (AOA). ...
... & Science University have discovered a naturally occurring disease in ... a discovery that could have a major impact on ... The disease that the researchers discovered in monkeys at OHSU,s ... virus that could give significant clues into how multiple sclerosis ...
Cached Medicine News:Health News:Research Sheds Light on Cause of Brain Deficits in HIV Patients 2Health News:Mid-Atlantic states' unique plan to replace region's dirtiest trucks 2Health News:Mid-Atlantic states' unique plan to replace region's dirtiest trucks 3Health News:Certain Cancer Drugs Don't Interfere With Flu Vaccine: Study 2Health News:Longest Trial Ever Confirms Mammograms' Benefits 2Health News:Longest Trial Ever Confirms Mammograms' Benefits 3Health News:Work to slow progression of nearsightedness in children wins award 2Health News:Researchers at Oregon Health & Science University discover MS-like disease in monkeys 2
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Sol, 80 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 20 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... Pachymeter [i.e., PalmScan P2000] device is ... which incorporates A-mode pulsed-echo ultrasound,technology, and ... measure the corneal thickness (CT) and,epithelium ... P2000 includes two software user,interfaces; a ...
Medicine Products: